Evaluation Of Clinical Safety And Tolerance Of A Lactobacillus Reuteri NCIMB 30242 Supplement Capsule: A Randomized Control Trial
Notes for this study:
|Number of Subjects
Supplementation of _l. reuteri_ NCIMB 30242 at 2.9x10^9^ CFU twice daily in otherwise healthy hypercholesteromic adults for nine weeks did not appear to confer any significant toxic effects relative to placebo.
Funding issues for this study:
LDL cholesterol appeared to be reduced 11.7% with supplementation, but most other parameters were unchanged.
Funding provided by Micropharma, producer of Cardioviva